NOVO B enters the week in a rare position — a 23% monthly price recovery running alongside a lending market that is quietly loosening, even as short positioning has nearly tripled from its April lows.
The most telling move in the lending market is direction, not level. Cost to borrow has fallen sharply — from around 1.6% at the start of April to just over 1.0% now, an 18% drop on the week alone and 35% lower than a month ago. That easing reflects reduced competition among short sellers for available shares, consistent with a borrow market that is becoming less stressed. Availability remains low in absolute terms, but the trend is unambiguously in the direction of loosening. Short interest as a percentage of the free float remains modest at 0.27%, though it has climbed from a floor of roughly 0.10% in early April — nearly tripling over six weeks. That build is worth monitoring, but at these absolute levels it remains far from crowded.
The ORTEX short score of 27.2 tells the same story. The score has crept up for ten consecutive sessions — from 26.2 on May 1 to 27.2 now — but at that level it ranks well below any threshold of squeeze risk. Days to cover is a thin 1.7. The short score ranks in the 92nd percentile among peers, which reflects the stock's elevated profile more than any acute short-side pressure. The setup looks like early-stage accumulation by bears rather than an active campaign.
The broader investment case carries some notable tailwinds. Novo reported Q1 results on May 6, and the stock gained 3.4% on the day — a clean beat that cemented the month's recovery. Today brought a fresh catalyst: new oral Wegovy pill data was highlighted, with the REDEFINE-1 trial also presenting CagriSema body composition data at ECO 2026. At the same time, Eli Lilly's approval of lower-dose Zepbound and its sustained weight-loss data keeps competitive pressure real and visible. Novo also confirmed it has scrapped plans for a new Danish factory — a cost discipline signal that investors appear to have absorbed without alarm. Valuation has re-rated materially with the recovery: the PE has expanded by 2.6 turns over the past 30 days to 14x, and the price-to-book has risen by nearly a full turn to 5.6x. EV/EBITDA, by contrast, has edged lower over the same period to 9.98x. The EPS surprise percentile rank of 90 and dividend score of 98 support a quality argument that many holders anchor to.
Ownership is anchored by Novo Holdings at 28.25% — a controlling stake that never trades. Among the external managers, Vanguard added 6.4 million shares in Q1, while Norges Bank trimmed 8.4 million. BlackRock, JPMorgan Asset Management, and State Street all added modest positions through April. The insider data is dated to February; no fresh buying or selling has been filed since, so the signal there is absent. What the ownership structure does confirm is a deep institutional base with little evidence of meaningful rotation out.
Next in focus is the Q2 results, scheduled for 5 August. Between now and then, the key variables to watch are the cadence of oral GLP-1 data readouts — today's Wegovy pill headline underscores how rapidly the data calendar is moving — and any pricing or reimbursement news that could sharpen the competitive picture between Novo and Lilly ahead of summer.
See the live data behind this article on ORTEX.
Open NOVO B on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
